Tuyển tập báo cáo các nghiên cứu khoa học quốc tế ngành y học dành cho các bạn tham khảo đề tài: Clinical significance of 4 patients with chronic hepatitis B achieving HBsAg clearance by treated with pegylated interferon alpha-2a for less than 1 year: a short report | Virology Journal BioMed Central Open Access Short report Clinical significance of 4 patients with chronic hepatitis B achieving HBsAg clearance by treated with pegylated interferon alpha-2a for less than 1 year a short report Jin Yang1 and Lian-san Zhao 2 Address Department of Infectious Diseases Nanshan Affiliated Hospital of Guangdong Medical College Shenzhen 518052 China and 2Center of Infectious Diseases National Key Laboratory of Biotherapy for Human Diseases West China Hospital Sichuan University Chengdu 610041 Sichuan Province China Email JinYang-yjz-1234@ Lian-san Zhao - zlsan@ Corresponding author Published 8 July 2009 Received 24 April 2009 Virology Journal 2009 6 97 doi 1743-422X-6-97 Accepted 8 July 2009 This article is available from http content 6 1 97 2009 Yang and Zhao licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License http licenses by which permits unrestricted use distribution and reproduction in any medium provided the original work is properly cited. Abstract We report 4 chinese patients with hepatitis B e antigen-positive chronic hepatitis B achieving clearance of HBsAg by using pegylated interferon alpha-2a for less than I year to provide one clinical clue for the treatment of chronic hepatitis B. Background Chronic infection with Hepatitis B virus HBV is a major global health problem affecting 350-400 million people worldwide 1 2 . Patients who have HBV infection with positivity for hepatitis B e antigen HBeAg and persistently active disease have increased risks for progressive disease leading to liver cirrhosis and hepatocellular carci-noma 3 . Therefore for patients with HBeAg positive chronic hepatitis B CHB anti-viral therapy is most important if they have indications for treatment. The end points to assess efficacy of therapy include reduction of serum HBV DNA to the undetectable level .
